HAVCR2 and acute myeloid leukemia: As shown in Fig. 3B, expression of TIM-3 on target cells sensitized them to T-cell killing, a phenomenon that was further enhanced by addition of sabatolimab (but not sabatolimab antibody fragments), suggesting that the Fc-portion of sabatolimab may be important for sabatolimab-enhanced T-cell-mediated killing of TIM-3+ AML cells.